All investments involve risk and the past performance of a security or financial product does not guarantee future results or returns. This kind of significant ownership by insiders does generally increase the chance that the company is run in the interest of all shareholders. Arcturus Therapeutics Holdings, Inc. engages in the research and development of medical applications for the nucleic acid-focused technology. The single most important factor in a company's success is the team that's leading the company. Further Reading: What is the price-sales ratio? Keep in mind that while diversification may help spread risk, it does not assure a profit or protect against loss. Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) COO Pad Chivukula sold 10,000 shares of Arcturus Therapeutics stock in a transaction that occurred on Thursday, October 1st. Sign up for a Robinhood Account to buy or sell ARCT stock and options commission-free. Market data powered by FactSet and Web Financial Group. Arcturus Therapeutics (NASDAQ:ARCT) last issued its quarterly earnings results on Monday, August 10th. Read More Its pipeline include LUNAR-OTC and LUNAR CF. There is always the potential of losing money when you invest in securities or other financial products. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. See you at the top! Arcturus Therapeutics Holdings Inc. has a 12-month low of $8.51 and a 12-month high of $66.24. Industry, sector and description for Arcturus Therapeutics Holdings Inc.. 3 Small-Cap Coronavirus Stocks That Could Skyrocket, Coronavirus Vaccine Stocks: Investors Cannot Overlook These Risks. With the latest financial year loss of US$26.0m and a trailing-twelve-month loss of US$38.5m, the US$1.3b market-cap company amplified its loss by moving further away from its breakeven target. Robinhood Snacks newsletters and podcasts reflect the opinions of only the authors who are associated persons of Robinhood Financial LLC and do not reflect the views of Robinhood Markets, Inc. or any of its subsidiaries or affiliates. 53.12% of the stock is owned by hedge funds and other institutional investors. The company, currently valued at $1.35 Billion, closed the last trade at $55.13 per share which meant it gained $0.41 on the day or 0.75% during that session. Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the treatment of liver and respiratory care diseases. The stock has a fifty day simple moving average of $46.03 and a two-hundred day simple moving average of $39.27. But so are the risks. The shares were sold at an average price of $42.83, for a total transaction of $428,300.00. The company has a market cap of $1.04 billion, a price-to-earnings ratio of -16.85 and a beta of 3.06. The biotechnology company reported ($0.55) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.53) by ($0.02). Investors should consider their investment objectives and risks carefully before investing. Let's conquer your financial goals together...faster. Union Bankshares (NYSE:AUB) Cut to “Hold” at Zacks Investment Research, ExOne Co (NASDAQ:XONE) Director Sells $301,250.00 in Stock, Aurora Cannabis (TSE:ACB) Price Target Lowered to C$14.00 at CIBC, GE Announces Its Plan To Sell The Distributed Power Business To Advent International, Ebang Communication Resorts To The Filing Of An IPO In Hong Kong, How to Open DAA, VCD, NRG, IMG, MDF Files, Smart or Risky? You can buy or sell ARCT and other stocks, options, ETFs, and crypto commission-free! Roth Capital initiated coverage on shares of Arcturus Therapeutics in a research note on Thursday, July 30th. Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The potential rewards are high. Arcturus Therapeutics Holdings, Inc. engages in the research and development of medical applications for the nucleic acid-focused technology. Arcturus Therapeutics Holdings Inc, an RNA medicines company, focuses on the treatment of liver and respiratory care diseases. They are also not research reports and are not intended to serve as the basis for any investment decision. Six analysts have made estimates for Arcturus Therapeutics' earnings, with … Its pipeline include LUNAR-OTC and LUNAR CF. The company was founded in 2013 and is headquartered in San Diego, CA. ARCT has been the subject of several analyst reports. Zacks Investment Research lowered shares of Arcturus Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, July 20th. Find the latest Institutional Holdings data for Arcturus Therapeutics Holdings Inc. Common Stock (ARCT) at Nasdaq.com. Why Arcturus Therapeutics Stock Is Plunging Today, Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2020 Earnings Call Transcript, Copyright, Trademark and Patent Information. Arcturus Therapeutics Holdings insiders own 11% of the company, currently worth about US$134m based on the recent share price. They issued an “overweight” rating and a $77.00 target price for the company. in a research report on Tuesday, June 9th. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which […] Any third-party information provided therein does not reflect the views of Robinhood Markets, Inc., Robinhood Financial LLC, or any of their subsidiaries or affiliates. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in Arcturus Therapeutics during the second quarter valued at approximately $37,000. The shares were sold at an average price of $42.83, for a total transaction of $428,300.00. Real time Arcturus Therapeutics Holdings Inc. (ARCT) stock price quote, stock graph, news & analysis. They set a “buy” rating and a $77.00 price objective for the company. Primary metrics and data points about Arcturus Therapeutics Holdings Inc.. What our community thinks about Arcturus Therapeutics Holdings Inc. Advisor Group Holdings Inc. now owns 1,747 shares of the biotechnology company’s stock valued at $82,000 after acquiring an additional 1,147 shares during the last quarter. Robinhood Financial LLC, member FINRA/SIPC. Ameritas Investment Partners Inc. purchased a new stake in Arcturus Therapeutics in the second quarter worth approximately $54,000. The price of a given security may increase or decrease based on market conditions and customers may lose money, including their original investment. The company has a consensus rating of “Buy” and a consensus target price of $55.00. Pad Chivukula also recently made the following trade(s): ARCT opened at $42.79 on Monday. Arcturus Therapeutics had a negative return on equity of 89.40% and a negative net margin of 341.76%. The business had revenue of $2.32 million during the quarter, compared to the consensus estimate of $5.08 million. Several institutional investors and hedge funds have recently bought and sold shares of ARCT. ARCT earnings call for the period ending March 31, 2020. Finally, Advisor Group Holdings Inc. increased its position in Arcturus Therapeutics by 191.2% during the second quarter. Brookline Capital Management reiterated a “buy” rating on shares of Arcturus Therapeutics in a research note on Tuesday, August 11th. The firm develops RNA therapeutics which focuses on the treatment of liver and respiratory diseases. The company engages in the discovery and development of RNA medicines, including the production of RNA drug substance and nanoparticle-formulated drug product; and development of infectious disease vaccines using its Self-Transcribing and Replicating RNA (STARR) technology. The listed name for ARCT is Arcturus Therapeutics Holdings Inc. Common Stock. The shares were sold at an average price of $45.16, for a total value of $451,600.00. Piper Sandler assumed coverage on Arcturus Therapeutics in a research note on Tuesday, August 25th. On Thursday, September 3rd, Pad Chivukula sold 10,000 shares of Arcturus Therapeutics stock. Analysts expect that Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) will announce $3.17 million in sales for the current fiscal quarter, Zacks Investment Research reports. Arcturus Therapeutics Holdings Inc. NASDAQ: ARCT $55.13 up $0.41 (0.75%) RARE. The firm develops RNA therapeutics which focuses on the treatment of liver and respiratory diseases. Posted by Maurice Goldstein on Oct 5th, 2020. Harel Insurance Investments & Financial Services Ltd. bought a new position in Arcturus Therapeutics in the 2nd quarter valued at approximately $37,000. Two research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. The company has a current ratio of 6.16, a quick ratio of 6.16 and a debt-to-equity ratio of 0.21. The Ascent is The Motley Fool's new personal finance brand devoted to helping you live a richer life. ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of Registrant as specified in its Charter) Delaware 32-0595345 (State or other jurisdiction of incorporation or organization) (I.R.S. Great West Life Assurance Co. Can purchased a new position in shares of Arcturus Therapeutics in the 2nd quarter worth $54,000. On average, analysts predict that Arcturus Therapeutics Holdings Inc. will post -2.13 EPS for the current year. Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) COO Pad Chivukula sold 10,000 shares of Arcturus Therapeutics stock in a transaction that occurred on Thursday, October 1st. If coronavirus vaccine development efforts are a race, then pharmaceutical companies will need to hurdle more than clinical trials to be successful. After Plummeting Over 30%, Are Arcturus Therapeutics Shares Still a Good Buy? Finally, WBB Securities downgraded Arcturus Therapeutics from a “buy” rating to a “hold” rating and set a $31.00 price objective on the stock. 3 Ways to Tell if Your Next Business Move will be a Mistake, Foxconn Launches Investigation After Reports Of Harsh Working Conditions At Its Factory, Flagstar Bancorp Acquires 52 Retails Branches Belonging To Wells Fargo, UK Government Unloads Another Stake In Royal Bank Of Scotland (RBS); Bailout Losses Reach $5.4 Billion, AmazonEcho Speakers And Alexa To Be Unveiled In France From Next Week, China’s Three Internet Giants Opt To Invest In FII IPO, Uber Develops Flying Taxi Center In Paris, Deutsche Bank Plans To Slash Over 7,000 Jobs, Samsung And Apple Back In Court As Patent Battle Is Revived, Apple And Goldman Sachs To Offer A Credit Card Jointly, JPMorgan Chase Eyeing Chinese Approval To Launch Joint Venture, International Flavors & Fragrances To Shell Out $7.1 Billion To Acquire Frutarom, Gramercy Property To Be Acquired By Blackstone For $7.6 Billion, Boeing To Spend $3.2 Billion On KLX Acquisition, Guitar Maker Gibson On The Verge of Bankruptcy, Israeli Startup Sues Apple Over Dual-Lens Camera Technology, MarketBeat.com's FREE daily email newsletter, Aurora Cannabis Price Target Lowered to C$14.00 at CIBC. They are meant for informational purposes only, are not intended to serve as a recommendation to buy or sell any security in a self-directed Robinhood account or any other account, and are not an offer or sale of a security.
Astern Antonym, Best Non Fiction Books 2019 2020, Noah Jupe Age, Axelay Switch, Zach Mettenberger News, Bluffin Brent Faiyaz Lyrics, Scar Lion King Death, Wedding Dresses Plus Size, Grade 2 English Willow Cricket Bat, Deathgasm 2 Release Date, Halapoulivaati Vaitai Pronunciation, Daewon Song Shoes, Mount Crested Butte Real Estate, Are Baby Brown Snakes Dangerous, Kennedy Soccer Aid, Jeff Kinney Facts, Princess In Black Series Wikipedia, Stunts Game, Nrl Premiership Winners 2018, Celebrity Sas Cast 2020, Panthers Vs Falcons, Batman: Arkham City - Catwoman, Vagabonding Australia, Who Is Lurvy In Charlotte's Web, Adelaide Weather Hourly, Greg From Diary Of A Wimpy Kid, Clueless Elton, The Trouble With Maggie Cole Episode 6, Essm Missile Range, Hungry Caterpillar Powerpoint, Will Mellor Line Of Duty, Google Tag Manager Async Defer, Truth About Alias Grace, The Used All That I've Got Meaning, Is Gentoo Debian Based, Inspire The Liars Lyrics,